Latest filing published 28 Nov 2023 for Sangamo Therapeutics, INC, €674.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David Mark McClung: trading record in brief
David Mark McClung (senior executive) discloses dealings in Sangamo Therapeutics, Inc to SEC (Form 4). The record holds 12 filings, for trades running from 25 June 2020 to 25 November 2023.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The record was last updated on 28 November 2023 with a share grant (€674) in Sangamo Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to David Mark McClung
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,925 shares@ US$0.38210.2% of flowCommon StockSEC:0001209191-23-056788:0
- 1,925 shares@ US$0.770.4% of flowCommon StockSEC:0001209191-23-047586:0
- 11,528 shares@ US$1.193.9% of flowCommon StockSEC:0001209191-23-039711:0
- 1,925 shares@ US$1.330.7% of flowCommon StockSEC:0001209191-23-032910:0
- 56,250 shares0Common StockSEC:0001209191-23-016395:0
- 11,525 shares@ US$4.310.032% mcap15.5% of flowCommon StockSEC:0001209191-22-039649:0
- 4,610 shares@ US$5.9011.9% of flowCommon StockSEC:0001209191-22-014167:0
- 11,525 shares@ US$12.0256.7% of flowCommon StockSEC:0001209191-21-043811:0
8 of 8 declarations
